1. Scrip

Takeda Continues To Shed Pipeline Assets In Roivant Deal

 
• By Ian Haydock

Takeda has set up a new company with Roivant to expedite the development of relugolix, an oral GnRH antagonist, for indications including prostate cancer and endometriosis.

In a move that marks a continued shedding of selected non-core assets, Takeda Pharmaceutical Co. Ltd. has set up with partner Roivant Sciences Ltd. a new company to develop a late clinical stage molecule that has shown potential in both oncology and women's health indications.

Myovant Sciences has been established based on the granting to it of an exclusive worldwide license - excluding commercial rights...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Focus On Asia

More from Scrip

J&J’s Trispecific Antibody For Myeloma Offers Improved Safety, Potency Over Bispecifics

 
• By Alaric DeArment

The drugmaker presented data from its Phase I study of JNJ-79635322 at ASCO and EHA showing a 100% response rate in BCMA- and GPRC5D-naïve patients.

Defying Gravity: Five Drugs That Surpassed Their Sales Forecasts

 
• By Edwin Elmhirst

Many assets outperform their pre-launch sales predictions despite the frequent overestimation of forecasts within the industry. In this article, Scrip highlights several such assets and the factors that influenced their predictions.

Executives On The Move: Fable Therapeutics Gains CMO From AstraZeneca

Recent moves in the industry include changes at the top at 32 Biosciences, plus new CEOs at Idorsia, Courage Therapeutics and Oncolytics Biotech.